Mario Toriello, 1. CEINGE–Biotecnologie Avanzate S.C.a r.l., Naples, Italy
1 Pasquale Meccariello, 2. Dipartimento Clinico di Medicina Interna, Geriatria, Patologia Cardiovascolare e Immunitaria e Cardiochirurgia, Naples, Italy
2 Cristina Mazzaccara, 3. CEINGE–Biotecnologie Avanzate S.C.a r.l., Naples, Italy and Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, via S. Pansini 5, Naples, Italy
3 Rosanna Di Fiore, 4. CEINGE–Biotecnologie Avanzate S.C.a r.l., Naples, Italy and Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, via S. Pansini 5, Naples, Italy
4 Carmela Esposito, 5. Dipartimento Clinico di Medicina Interna, Geriatria, Patologia Cardiovascolare e Immunitaria e Cardiochirurgia, Naples, Italy
5 Lucia Sacchetti6. CEINGE–Biotecnologie Avanzate S.C.a r.l., Naples, Italy and Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, via S. Pansini 5, Naples, Italy
6 Corresponding author: Lucia Sacchetti, Dipartimento di Biochimica e Biotecnologie Mediche, Università di Napoli Federico II, via S. Pansini 5, 80131 Naples, Italy Phone: +39-081-7463532, Fax: +39-081-7462404,
Citation Information. Clinical Chemical Laboratory Medicine. Volume 44, Issue 3, Pages 285–287, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2006.049, 01/03/2006
Publication History: Received: //; accepted: //; published online: 07/03/2006
Abstract
Background: Pharmacogenetic testing for drug-metabolizing enzymes is not yet widely used in clinical practice.
Methods: In an attempt to facilitate the application of this procedure, we have compared two real-time PCR-based methods, the TaqMan® and the LightCycler™ for the pharmacogenetic evaluation of CYP2C9*2/*3 polymorphisms.
Results and Conclusion: Both procedures are suitable for pharmacogenetic studies. The TaqMan procedure was less expensive in terms of cost per sample, but the TaqMan apparatus is more expensive than the LightCycler apparatus.
Keywords cytochrome P450 (CYP450), pharmacogenetic testing, polymorphisms
